A

Arctic Bioscience AS
OSE:ABS

Watchlist Manager
Arctic Bioscience AS
OSE:ABS
Watchlist
Price: 3.39 NOK 4.63% Market Closed
Market Cap: 91.1m NOK

Wall Street
Price Targets

ABS Price Targets Summary
Arctic Bioscience AS

Wall Street analysts forecast ABS stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABS is 2.55 NOK with a low forecast of 2.53 NOK and a high forecast of 2.63 NOK.

Lowest
Price Target
2.53 NOK
26% Downside
Average
Price Target
2.55 NOK
25% Downside
Highest
Price Target
2.63 NOK
23% Downside
Arctic Bioscience AS Competitors:
Price Targets
2162
KeyMed Biosciences Inc
63% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
64% Upside
002007
Hualan Biological Engineering Inc
26% Upside
RCUS
Arcus Biosciences Inc
40% Upside
ANAB
AnaptysBio Inc
14% Upside
196170
Alteogen Inc
20% Upside

Revenue
Forecast

Revenue Estimate
Arctic Bioscience AS

For the last 4 years the compound annual growth rate for Arctic Bioscience AS's revenue is 21%. The projected CAGR for the next 2 years is 49%.

21%
Past Growth
49%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Arctic Bioscience AS

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
17%
Average Beat

Net Income
Forecast

Net Income Estimate
Arctic Bioscience AS

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABS's stock price target?
Price Target
2.55 NOK

According to Wall Street analysts, the average 1-year price target for ABS is 2.55 NOK with a low forecast of 2.53 NOK and a high forecast of 2.63 NOK.

What is Arctic Bioscience AS's Revenue forecast?
Projected CAGR
49%

For the last 4 years the compound annual growth rate for Arctic Bioscience AS's revenue is 21%. The projected CAGR for the next 2 years is 49%.

Back to Top